Nepexto Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of biologic drug usage in autoimmune diseases, rising healthcare cost containment efforts, regulatory approvals for biosimilars, increasing prevalence of autoimmune disorders, availability of reference biologic alternatives.

The growth in the forecast period can be attributed to increasing penetration of biosimilars in specialty care, growing payer support for biosimilar substitution, expansion of outpatient biologic treatment, rising demand for self-injectable therapies, increasing global regulatory alignment. Major trends in the forecast period include increasing adoption of biosimilar therapies, rising demand for cost-effective autoimmune treatments, growing physician confidence in biosimilars, expansion of injectable biologic delivery formats, enhanced focus on regulatory harmonization.

The increasing prevalence of chronic diseases is expected to propel the growth of the nepexto market going forward. A chronic disease is a long-term condition that typically lasts longer than three months and often requires continuous medical care or restricts everyday activities. The rise in chronic diseases is driven by factors such as aging populations, unhealthy lifestyle habits, and advances in medical treatment that enable individuals with acute illnesses to live longer, thereby increasing the burden of long-term conditions. Nepexto is used in managing chronic autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis, providing a cost-effective and accessible option for long-term disease control. For instance, in November 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, noncommunicable diseases were responsible for 41 million deaths annually, accounting for 74% of global deaths. Each year, 17 million people die prematurely from NCDs before the age of 70, with 86% of these deaths occurring in low- and middle-income countries. Cardiovascular diseases lead NCD-related deaths at 17.9 million annually, followed by cancers at 9.3 million, chronic respiratory diseases at 4.1 million, and diabetes. Together, these conditions represent more than 80% of all premature NCD-related deaths. Therefore, the growing prevalence of chronic diseases is driving the growth of the nepexto market.

The rise in healthcare expenditure is expected to further drive the growth of the nepexto market going forward. Healthcare expenditure refers to total spending on healthcare products and services, including personal medical care, preventive services, and public health initiatives aimed at improving health outcomes over a defined period. Healthcare spending is increasing due to factors such as population aging, the growing burden of chronic diseases, advancements in medical technology, high drug costs, inefficient payment systems, and rising demand for healthcare services. Nepexto supports effective use of healthcare expenditure by offering a cost-efficient treatment option for chronic autoimmune diseases, helping optimize healthcare resources while maintaining patient access to advanced biologic therapies. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental organization, average healthcare spending across OECD countries in 2024 was estimated at nearly USD 6,000 per capita, with the United States being the highest spender. Therefore, the increase in healthcare expenditure is driving the growth of the nepexto market.

Major companies operating in the nepexto market are focusing on the development of biosimilars, such as etanercept, to strengthen their competitive position. Etanercept biosimilars are biologic medicines designed to closely match the structure, function, and therapeutic effectiveness of the original etanercept, and are primarily used in the treatment of autoimmune diseases. For instance, in May 2024, Lupin, an India-based pharmaceutical company, partnered with Sandoz, a Switzerland-based pharmaceutical company, to launch Rymti, an etanercept biosimilar, in Canada. Rymti is expected to expand treatment choices for patients with chronic inflammatory conditions while offering a more affordable alternative to existing therapies, supporting sustainable healthcare solutions.

Major companies operating in the nepexto market are Lupin Limited.

Europe was the largest region in the nepexto market in 2025. The regions covered in the nepexto market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nepexto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the nepexto market by increasing costs of imported biologic raw materials, cell culture media, single-use bioprocessing components, and injectable drug delivery systems. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces higher production input costs. These tariffs can increase treatment costs and slow biosimilar adoption in price-sensitive markets. However, they are also driving investments in local biologics manufacturing, regional fill-finish capacity, and supply chain diversification for biosimilar medicines.

The nepexto market research report is one of a series of new reports that provides nepexto market statistics, including nepexto industry global market size, regional shares, competitors with a nepexto market share, detailed nepexto market segments, market trends and opportunities, and any further data you may need to thrive in the nepexto industry. This nepexto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nepexto is a biosimilar medication developed to offer an alternative treatment option for patients with autoimmune diseases. It is designed to closely match the reference biologic in terms of safety, efficacy, and quality. Nepexto is commonly used to manage conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, providing patients with a more cost-effective and accessible therapy.

The primary indication types for Nepexto include growth hormone deficiency, idiopathic short stature, Turner syndrome, and Prader-Willi syndrome. Growth hormone deficiency (GHD) is a medical condition resulting from insufficient production of growth hormone by the pituitary gland, leading to impaired growth in children and metabolic abnormalities in adults. Nepexto is available in injectable solution formulations, including pre-filled syringes or pens, and is distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies. It is used by both adult and pediatric patients.

The nepexto market consists of sales of biologics, biosimilars, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.